Halozyme initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Halozyme Therapeutics with a Buy rating and $61 price target. Halozyme is a biopharmaceutical technology platform company focused on improving patient experiences and outcomes, the analyst tells investors in a research note. The firm says the company is improving the way that drugs are administered and delivered.